KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest Expenses (2018 - 2025)

Historic Interest Expenses for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Aurinia Pharmaceuticals' Interest Expenses fell 902.32% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 1140.23%. This contributed to the annual value of $4.8 million for FY2024, which is 7423.42% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Interest Expenses of $1.1 million as of Q3 2025, which was down 902.32% from $1.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Interest Expenses high stood at $1.4 million for Q3 2023, and its period low was -$204000.0 during Q4 2021.
  • Its 4-year average for Interest Expenses is $971727.3, with a median of $1.1 million in 2024.
  • In the last 5 years, Aurinia Pharmaceuticals' Interest Expenses surged by 174307.69% in 2024 and then tumbled by 1683.55% in 2025.
  • Quarter analysis of 4 years shows Aurinia Pharmaceuticals' Interest Expenses stood at -$204000.0 in 2021, then skyrocketed by 742.16% to $1.3 million in 2023, then fell by 12.52% to $1.1 million in 2024, then dropped by 4.1% to $1.1 million in 2025.
  • Its Interest Expenses stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.